SCHEMBL14437446

SCHEMBL14437446

COc1ccc(-c2cc(C(=O)O)c3cc(Cl)ccc3n2)c(O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.69
▸ PLA2G2A P14555 2/20 0.63
▸ DHODH Q02127 6/20 0.58
▸ POLB P06746 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ ALDH1A1 P00352 3/20 0.57
▸ HPGD P15428 3/20 0.57
▸ CYP2C9 P11712 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ PTGES O14684 1/20 0.57
▸ ALOX5 P09917 1/20 0.57
▸ CASP7 P55210 1/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ CYP2D6 P10635 1/20 0.56
▸ CA12 O43570 2/20 0.52
▸ CA1 P00915 2/20 0.52
▸ CA2 P00918 2/20 0.52
▸ CA9 Q16790 2/20 0.52
▸ AURKA O14965 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5531759 0.85 KDM4E (0.88) KDM4EPLA2G2ADHODHMEN1KMT2A
SCHEMBL8231320 0.84 DHODH (0.70) KDM4EPLA2G2ADHODHMEN1KMT2A
SCHEMBL23590069 0.84 KDM4E (0.86) KDM4EPLA2G2ADHODHKMT2AALDH1A1
SCHEMBL29617657 0.84 KDM4E (0.86) KDM4EPLA2G2ADHODHKMT2AALDH1A1
SCHEMBL23590087 0.81 KDM4E (0.69) KDM4EPLA2G2ADHODHMEN1KMT2A
SCHEMBL23590223 0.78 KDM4E (0.68) KDM4EPLA2G2ADHODHPOLBMEN1
SCHEMBL7823061 0.78 KDM4E (0.79) KDM4EPLA2G2ADHODHPOLBMEN1
SCHEMBL4017807 0.76 CYP2D6 (0.65) KDM4EPLA2G2ADHODHPOLBMEN1
SCHEMBL14825176 0.75 KDM4E (0.73) KDM4EPLA2G2ADHODHPOLBMEN1
SCHEMBL27491756 0.75 KDM4E (0.71) KDM4EPLA2G2ADHODHPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197509-A1 Compositions and methods for modulating gated ion channels PAINCEPTOR PHARMA CORPORATION (CA) 2007-08-23 — — US disclosed
US-20070197509-A1 Compositions and methods for modulating gated ion channels PAINCEPTOR PHARMA CORPORATION (CA) 2007-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197509-A1 Compositions and methods for modulating gated ion channels KCNN3, KCNN2, HCN3 KDM4E 2625/4885PLA2G2A 246/4885DHODH 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback